Satta G, Cornaglia G, Foddis G, Pompei R
Istituto di Microbiologia, Università degli Studi di Siena, Italy.
Antimicrob Agents Chemother. 1988 Apr;32(4):552-60. doi: 10.1128/AAC.32.4.552.
In pursuit of an in vitro system capable of reliably predicting the activities of antibiotics in serious infections and in infections occurring in immunocompromised hosts, we evaluated the abilities of four drugs to achieve virtually complete killing of bacterial cells growing in human body fluids in amounts which are very high and close to those likely to be present in serious infections; drug concentrations varied with time as they vary in human bronchial secretions or blood or urine (dynamic concentrations). The rationale for such a test was (i) to set up in vitro conditions as close as possible to those the antibiotics encounter in serious infections and (ii) to hold the drugs capable of almost completely killing the bacteria used in the assay to be highly active in vitro and likely to be the most efficacious in the treatment of serious infections. Among the antibiotics used, ceftriaxone proved to be highly active under conditions simulating pulmonary infections and septicemias caused by Streptococcus pneumoniae (bacteria grown in bronchoalveolar fluid or blood; antibiotic concentrations varying with time as in human bronchial secretions or blood) and under conditions simulating blood and urinary infections caused by Escherichia coli (bacteria grown in human blood or urine; antibiotic concentrations varying as in the various fluids). Gentamicin (not tested against pneumococci) appeared to be highly active only under conditions simulating urinary infections caused by E. coli; aztreonam (not tested against pneumococci) and ampicillin (tested only against pneumococci) did not appear to be highly active under any of the test conditions. Only the combination of gentamicin plus either ceftriaxone or aztreonam appeared to be highly active under conditions simulating serious septicemias and urinary infections caused by Psudomonas aeruginosa.
为了寻求一种能够可靠预测抗生素在严重感染以及免疫功能低下宿主中发生的感染中的活性的体外系统,我们评估了四种药物在人体体液中对生长细菌实现几乎完全杀灭的能力,这些体液中的药物含量非常高且接近严重感染中可能出现的含量;药物浓度随时间变化,如同它们在人支气管分泌物、血液或尿液中变化一样(动态浓度)。进行这种测试的基本原理是:(i)建立尽可能接近抗生素在严重感染中所遇到的体外条件;(ii)使能够几乎完全杀灭用于测定的细菌的药物在体外具有高活性,并可能在治疗严重感染中最有效。在所使用的抗生素中,头孢曲松在模拟由肺炎链球菌引起的肺部感染和败血症的条件下(细菌在支气管肺泡液或血液中生长;抗生素浓度如同在人支气管分泌物或血液中一样随时间变化)以及在模拟由大肠杆菌引起的血液和泌尿系统感染的条件下(细菌在人血液或尿液中生长;抗生素浓度在各种体液中变化)均表现出高活性。庆大霉素(未针对肺炎球菌进行测试)似乎仅在模拟由大肠杆菌引起的泌尿系统感染的条件下具有高活性;氨曲南(未针对肺炎球菌进行测试)和氨苄西林(仅针对肺炎球菌进行测试)在任何测试条件下似乎都没有高活性。只有庆大霉素与头孢曲松或氨曲南的组合在模拟由铜绿假单胞菌引起的严重败血症和泌尿系统感染的条件下似乎具有高活性。